Completed PHASE3 NCT00195676

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab

Sponsor: Abbott

Conditions Psoriasis

Interventions adalimumab

Updated 7 times since 2017 Last updated: Apr 11, 2011 Started: May 31, 2004 Primary completion: Oct 31, 2009 Completion: Oct 31, 2009

A PHASE3 clinical study on Psoriasis, this trial is completed. The trial is conducted by Abbott and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alpharetta, United States , Andover, United States , Ann Arbor, United States , Bakersfield, United States , Birmingham, United States , Boston, United States , Brussels, Belgium , Buckner 13075 PI, United States , Cagaus, Puerto Rico , Calgary, Canada and 85 more locations